Related Experiment Videos
Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white
T Tomita1, O Yokosuka, M Tagawa
1First Department of Medicine, Chiba University School of Medicine, Japan.
Journal of Hepatology
|June 14, 2000
Summary
Lamivudine effectively reduces duck hepatitis B virus (DHBV) DNA in serum and liver by inhibiting viral replication. However, complete viral clearance requires additional therapies beyond long-term lamivudine monotherapy.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Hepatitis B virus (HBV) infection is a global health concern.
- Lamivudine is an antiviral drug used for chronic hepatitis B.
- Its impact on intrahepatic HBV replication requires further investigation.
Purpose of the Study:
- To evaluate the effect of lamivudine on wild-type and precore mutant duck hepatitis B virus (DHBV) replication.
- To assess lamivudine's efficacy in both liver and serum of DHBV carrier ducks.
Main Methods:
- Chronic DHBV carrier ducks were treated with low-dose or high-dose lamivudine for 2 or 12 weeks.
- Serum DHBV DNA levels were measured using slot-blot hybridization.
- Intrahepatic viral replicative intermediates were analyzed by slot, Southern, and Northern blot.
Main Results:
- Lamivudine significantly reduced serum DHBV DNA levels in both wild-type and precore mutant carriers.
- Intrahepatic DHBV DNA replicative forms decreased in treated ducks.
- Covalently closed circular DNA and RNA intermediates showed less change.
Conclusions:
- Lamivudine inhibits DHBV replication, likely by affecting reverse transcription.
- Complete viral elimination from the liver is challenging with lamivudine monotherapy alone.
- Additional therapeutic strategies may be necessary for complete viral clearance.